Abraham C F Leung - JoVE Visualize

Showing results (1-10 of 5) with videos related to

Pageof 1

Sort By:

CPT: Pharmacometrics & Systems Pharmacology|May 12, 2026

Adaptive Dosing Trial Simulation Framework to Inform Dose Optimization: Case Study Using Longitudinal PKPD Models With PF-06804103 Phase 1 Data in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive and Low Solid TumorsJerry Li, Li Zhou, Abraham C F Leung, et al.

The Lancet. Oncology|May 6, 2014

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trialIan E Krop, Sung-Bae Kim, Antonio González-Martín, et al.

Molecular Cancer Therapeutics|July 7, 2023

Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation StudyFunda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee, et al.

Cancer Discovery|August 30, 2018

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudyAntoni Ribas, Theresa Medina, Shivaani Kummar, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2013

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancerIgnace B Vergote, Agustin Garcia, John Micha, et al.

Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:

Pageof 1

CPT: Pharmacometrics & Systems Pharmacology|May 12, 2026

Adaptive Dosing Trial Simulation Framework to Inform Dose Optimization: Case Study Using Longitudinal PKPD Models With PF-06804103 Phase 1 Data in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive and Low Solid TumorsJerry Li, Li Zhou, Abraham C F Leung, et al.

The Lancet. Oncology|May 6, 2014

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trialIan E Krop, Sung-Bae Kim, Antonio González-Martín, et al.

Molecular Cancer Therapeutics|July 7, 2023

Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation StudyFunda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee, et al.

Cancer Discovery|August 30, 2018

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudyAntoni Ribas, Theresa Medina, Shivaani Kummar, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2013

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancerIgnace B Vergote, Agustin Garcia, John Micha, et al.

Pageof 1